PDF herunterladen
Semin Neurol 2017; 37(02): 158-166
DOI: 10.1055/s-0037-1602424
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Nonmotor Symptoms in Parkinson's Disease

Umer Akbar
1   Department of Neurology, Brown University, Providence, Rhode Island
2   Department of Neurology, Rhode Island Hospital, Providence, Rhode Island
,
Anelyssa D'Abreu
1   Department of Neurology, Brown University, Providence, Rhode Island
2   Department of Neurology, Rhode Island Hospital, Providence, Rhode Island
,
Joseph H. Friedman
1   Department of Neurology, Brown University, Providence, Rhode Island
3   Department of Neurology, Butler Hospital, Providence, Rhode Island
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Mai 2017 (online)

    Lizenzen und Reprints

Abstract

Nonmotor symptoms (NMSs) in Parkinson's disease (PD) have become increasingly recognized as major determinants of quality of life across cultures worldwide. Behavioral symptoms include dementia, depression, anxiety, apathy, and fatigue. Somatic symptoms include hypotension, constipation, diaphoresis, and pain. However, somatic symptoms may also be intrinsic, such as dementia, and iatrogenic, such as compulsive disorders. The authors address some of the more common disorders, yet few have been the target of clinical trials.

Keywords

nonmotor symptoms - Parkinson's disease - fatigue - dementia - psychosis
 

  • References

  • 1 Weintraub D, Simuni T, Caspell-Garcia C. , et al; Parkinson's Progression Markers Initiative. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord 2015; 30 (07) 919-927
    CrossrefPubMedGoogle Scholar
  • 2 Emre M, Aarsland D, Brown R. , et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22 (12) 1689-1707 , quiz 1837
    CrossrefPubMedGoogle Scholar
  • 3 Aarsland D, Andersen K, Larsen JP. , et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61 (12) 1906-1911
    PubMedGoogle Scholar
  • 4 Kalbe E, Rehberg SP, Heber I. , et al. Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry 2016; 87 (10) 1099-1105
    CrossrefPubMedGoogle Scholar
  • 5 de Lau LM, Verbaan D, Marinus J, van Hilten JJ. Survival in Parkinson's disease. Relation with motor and non-motor features. Parkinsonism Relat Disord 2014; 20 (06) 613-616
    CrossrefPubMedGoogle Scholar
  • 6 Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 2010; 75 (14) 1270-1276
    CrossrefPubMedGoogle Scholar
  • 7 Pigott K, Rick J, Xie SX. , et al. Longitudinal study of normal cognition in Parkinson disease. Neurology 2015; 85 (15) 1276-1282
    CrossrefPubMedGoogle Scholar
  • 8 Cereda E, Cilia R, Klersy C. , et al. Dementia in Parkinson's disease: Is male gender a risk factor?. Parkinsonism Relat Disord 2016; 26: 67-72
    CrossrefPubMedGoogle Scholar
  • 9 Anang JB, Gagnon J-F, Bertrand J-A. , et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 2014; 83 (14) 1253-1260
    CrossrefPubMedGoogle Scholar
  • 10 Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010; 133 (Pt 6): 1755-1762
    CrossrefPubMedGoogle Scholar
  • 11 Monchi O, Hanganu A, Bellec P. Markers of cognitive decline in PD: The case for heterogeneity. Parkinsonism Relat Disord 2016; 24: 8-14
    CrossrefPubMedGoogle Scholar
  • 12 Williams-Gray CH, Evans JR, Goris A. , et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132 (Pt 11): 2958-2969
    CrossrefPubMedGoogle Scholar
  • 13 Mata IF, Leverenz JB, Weintraub D. , et al. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 2016; 31 (01) 95-102
    CrossrefPubMedGoogle Scholar
  • 14 Oeda T, Umemura A, Mori Y. , et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol Aging 2015; 36 (12) 3306-3313
    CrossrefPubMedGoogle Scholar
  • 15 Fuchs J, Nilsson C, Kachergus J. , et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007; 68 (12) 916-922
    CrossrefPubMedGoogle Scholar
  • 16 Chen B, Fan GG, Liu H, Wang S. Changes in anatomical and functional connectivity of Parkinson's disease patients according to cognitive status. Eur J Radiol 2015; 84 (07) 1318-1324
    CrossrefPubMedGoogle Scholar
  • 17 Hanganu A, Bedetti C, Degroot C. , et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain 2014; 137 (Pt 4): 1120-1129
    CrossrefPubMedGoogle Scholar
  • 18 Hanağası HA, Bilgiç B, Emre M. Dementia with Lewy bodies and Parkinson's disease dementia. In: Husain M, Schott JM. , eds. Oxford Textbook of Cognitive Neurology and Dementia. Oxford, England: Oxford University Press; 2016: 399-412
    CrossrefGoogle Scholar
  • 19 Szeto JY, Mowszowski L, Gilat M, Walton CC, Naismith SL, Lewis SJ. Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (01) 31-35
    CrossrefPubMedGoogle Scholar
  • 20 Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?. Mov Disord 2015; 30 (03) 402-406
    CrossrefPubMedGoogle Scholar
  • 21 Marras C, Tröster AI, Kulisevsky J, Stebbins GT. The tools of the trade: a state of the art “How to Assess Cognition” in the patient with Parkinson's disease. Mov Disord 2014; 29 (05) 584-596
    CrossrefPubMedGoogle Scholar
  • 22 Gustafsson H, Nordström A, Nordström P. Depression and subsequent risk of Parkinson disease: A nationwide cohort study. Neurology 2015; 84 (24) 2422-2429
    CrossrefPubMedGoogle Scholar
  • 23 Bulloch AG, Fiest KM, Williams JV. , et al. Depression--a common disorder across a broad spectrum of neurological conditions: a cross-sectional nationally representative survey. Gen Hosp Psychiatry 2015; 37 (06) 507-512
    CrossrefPubMedGoogle Scholar
  • 24 Inoue T, Kitagawa M, Tanaka T, Nakagawa S, Koyama T. Depression and major depressive disorder in patients with Parkinson's disease. Mov Disord 2010; 25 (01) 44-49
    CrossrefPubMedGoogle Scholar
  • 25 Riedel O, Bitters D, Amann U, Garbe E, Langner I. Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. Int J Geriatr Psychiatry 2016; 31 (08) 938-943
    CrossrefPubMedGoogle Scholar
  • 26 Hsu Y-T, Liao C-C, Chang S-N. , et al. Increased risk of depression in patients with Parkinson disease: a nationwide cohort study. Am J Geriatr Psychiatry 2015; 23 (09) 934-940
    CrossrefPubMedGoogle Scholar
  • 27 Wee N, Kandiah N, Acharyya S. , et al. Depression and anxiety are co-morbid but dissociable in mild Parkinson's disease: A prospective longitudinal study of patterns and predictors. Parkinsonism Relat Disord 2016; 23: 50-56
    CrossrefPubMedGoogle Scholar
  • 28 Kadastik-Eerme L, Rosenthal M, Paju T, Muldmaa M, Taba P. Health-related quality of life in Parkinson's disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes 2015; 13 (01) 83
    CrossrefPubMedGoogle Scholar
  • 29 Santos-García D, de la Fuente-Fernández R. Factors contributing to caregivers' stress and burden in Parkinson's disease. Acta Neurol Scand 2015; 131 (04) 203-210
    CrossrefPubMedGoogle Scholar
  • 30 Hu X, Song X, Yuan Y. , et al. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease. Mov Disord 2015; 30 (02) 238-244
    CrossrefPubMedGoogle Scholar
  • 31 Wen MC, Chan LL, Tan LC, Tan EK. Depression, anxiety, and apathy in Parkinson's disease: insights from neuroimaging studies. Eur J Neurol 2016; 23 (06) 1001-1019
    CrossrefPubMedGoogle Scholar
  • 32 Castrén E. Neuronal network plasticity and recovery from depression. JAMA Psychiatry 2013; 70 (09) 983-989
    CrossrefPubMedGoogle Scholar
  • 33 D'Ostilio K, Garraux G. The network model of depression as a basis for new therapeutic strategies for treating major depressive disorder in Parkinson's disease. Front Hum Neurosci 2016; 10: 161
    PubMedGoogle Scholar
  • 34 Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 2015; 21 (08) 833-842 , discussion 833
    CrossrefPubMedGoogle Scholar
  • 35 Adamson BC, Ensari I, Motl RW. Effect of exercise on depressive symptoms in adults with neurologic disorders: a systematic review and meta-analysis. Arch Phys Med Rehabil 2015; 96 (07) 1329-1338
    CrossrefPubMedGoogle Scholar
  • 36 Xie C-L, Chen J, Wang X-D. , et al. Repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in Parkinson disease: a meta-analysis of randomized controlled clinical trials. Neurol Sci 2015; 36 (10) 1751-1761
    CrossrefPubMedGoogle Scholar
  • 37 Shin H-W, Youn YC, Chung SJ, Sohn YH. Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson's disease. J Neurol 2016; 263 (07) 1442-1448
    CrossrefPubMedGoogle Scholar
  • 38 Borisovskaya A, Bryson WC, Buchholz J, Samii A, Borson S. Electroconvulsive therapy for depression in Parkinson's disease: systematic review of evidence and recommendations. Neurodegener Dis Manag 2016; 6 (02) 161-176
    CrossrefPubMedGoogle Scholar
  • 39 Dissanayaka NN, Sellbach A, Matheson S. , et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010; 25 (07) 838-845
    CrossrefPubMedGoogle Scholar
  • 40 Pontone GM, Williams JR, Anderson KE. , et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009; 24 (09) 1333-1338
    CrossrefPubMedGoogle Scholar
  • 41 Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol 2005; 96: 42-55
    PubMedGoogle Scholar
  • 42 Siemers ER, Shekhar A, Quaid K, Dickson H. Anxiety and motor performance in Parkinson's disease. Mov Disord 1993; 8 (04) 501-506
    CrossrefPubMedGoogle Scholar
  • 43 Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147 (02) 217-220
    CrossrefPubMedGoogle Scholar
  • 44 Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study. Mov Disord 2011; 26 (03) 484-492
    CrossrefPubMedGoogle Scholar
  • 45 Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4 (03) 257-264
    CrossrefPubMedGoogle Scholar
  • 46 Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Anxiety and motor fluctuations in Parkinson's disease: a cross-sectional observational study. Parkinsonism Relat Disord 2012; 18 (10) 1084-1088
    CrossrefPubMedGoogle Scholar
  • 47 Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and “on-off” phenomena in Parkinson's disease. Mov Disord 1990; 5 (02) 148-151
    CrossrefPubMedGoogle Scholar
  • 48 Prediger RD, Matheus FC, Schwarzbold ML, Lima MM, Vital MA. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology 2012; 62 (01) 115-124
    CrossrefPubMedGoogle Scholar
  • 49 Yang S, Sajatovic M, Walter BL. Psychosocial interventions for depression and anxiety in Parkinson's disease. J Geriatr Psychiatry Neurol 2012; 25 (02) 113-121
    CrossrefPubMedGoogle Scholar
  • 50 Marino L, Friedman JH. Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in Parkinson's disease. Intl J Neurosci 2012; 123 (01) 70-71
    PubMedGoogle Scholar
  • 51 Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015; 14 (05) 518-531
    CrossrefPubMedGoogle Scholar
  • 52 den Brok MG, van Dalen JW, van Gool WA, Moll van Charante EP, de Bie RM, Richard E. Apathy in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2015; 30 (06) 759-769
    CrossrefPubMedGoogle Scholar
  • 53 Maillet A, Krack P, Lhommée E. , et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease. Brain 2016; 139 (Pt 9): 2486-2502
    CrossrefPubMedGoogle Scholar
  • 54 Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988; 11 (06) 512-519
    CrossrefPubMedGoogle Scholar
  • 55 Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson's disease. A self-reported, community-based survey. Sleep Med 2002; 3 (02) 147-149
    CrossrefPubMedGoogle Scholar
  • 56 Arnulf I, Konofal E, Merino-Andreu M. , et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58 (07) 1019-1024
    CrossrefPubMedGoogle Scholar
  • 57 Maria B, Sophia S, Michalis M. , et al. Sleep breathing disorders in patients with idiopathic Parkinson's disease. Respir Med 2003; 97 (10) 1151-1157
    CrossrefPubMedGoogle Scholar
  • 58 Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46 (02) 388-393
    CrossrefPubMedGoogle Scholar
  • 59 Boeve BF, Silber MH, Parisi JE. , et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003; 61 (01) 40-45
    CrossrefPubMedGoogle Scholar
  • 60 Iranzo A, Santamaría J, Rye DB. , et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005; 65 (02) 247-252
    CrossrefPubMedGoogle Scholar
  • 61 Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003; 4 (04) 281-284
    CrossrefPubMedGoogle Scholar
  • 62 Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord 2015; 30 (02) 121-127
    CrossrefPubMedGoogle Scholar
  • 63 Kim J, Kim M, Kwon DY. , et al. Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. J Neurol 2013; 260 (02) 429-437
    CrossrefPubMedGoogle Scholar
  • 64 Fernandez HH, Friedman JH. Punding on L-dopa. Mov Disord 1999; 14 (05) 836-838
    CrossrefPubMedGoogle Scholar
  • 65 Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000; 11 (04) 185-186
    CrossrefPubMedGoogle Scholar
  • 66 Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 1972; 75 (03) 203-212
    PubMedGoogle Scholar
  • 67 Friedman JH, Agarwal P, Alcalay R. , et al. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. Int J Neurosci 2011; 121 (08) 472-476
    CrossrefPubMedGoogle Scholar
  • 68 Weintraub D, Koester J, Potenza MN. , et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67 (05) 589-595
    PubMedGoogle Scholar
  • 69 Lee J-Y, Kim J-M, Kim JW. , et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010; 16 (03) 202-207
    CrossrefPubMedGoogle Scholar
  • 70 Poletti M, Logi C, Lucetti C. , et al. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol 2013; 33 (05) 691-694
    CrossrefPubMedGoogle Scholar
  • 71 Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (02) 155-160
    CrossrefPubMedGoogle Scholar
  • 72 Antonini A, Siri C, Santangelo G. , et al. Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Mov Disord 2011; 26 (03) 464-468
    CrossrefPubMedGoogle Scholar
  • 73 Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65 (10) 1570-1574
    CrossrefPubMedGoogle Scholar
  • 74 Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014; 174 (12) 1930-1933
    CrossrefPubMedGoogle Scholar
  • 75 Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010; 33 (01) 81-87
    PubMedGoogle Scholar
  • 76 Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf) 2014; 80 (06) 863-868
    CrossrefPubMedGoogle Scholar
  • 77 Zhang S, Dissanayaka NN, Dawson A. , et al. Management of impulse control disorders in Parkinson's disease. Int Psychogeriatr 2016; 28 (10) 1-8
    PubMedGoogle Scholar
  • 78 Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30 (08) 587-592
    CrossrefPubMedGoogle Scholar
  • 79 Friedman JH, Brown RG, Comella C. , et al; Working Group on Fatigue in Parkinson's Disease. Fatigue in Parkinson's disease: a review. Mov Disord 2007; 22 (03) 297-308
    CrossrefPubMedGoogle Scholar
  • 80 Friedman J, Friedman H. Fatigue in Parkinson's disease. Neurology 1993; 43 (10) 2016-2018
    CrossrefPubMedGoogle Scholar
  • 81 Schifitto G, Friedman JH, Oakes D. , et al; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008; 71 (07) 481-485
    CrossrefPubMedGoogle Scholar
  • 82 Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133 (11) 3434-3443
    CrossrefPubMedGoogle Scholar
  • 83 Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8 (03) 193-197
    CrossrefPubMedGoogle Scholar
  • 84 Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007; 22 (14) 2070-2076
    CrossrefPubMedGoogle Scholar
  • 85 Giuffrida R, Vingerhoets FJ, Bogousslavsky J, Ghika J. [Pain in Parkinson's disease]. Rev Neurol (Paris) 2005; 161 (04) 407-418
    CrossrefPubMedGoogle Scholar
  • 86 Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15 (06) 1112-1118
    CrossrefPubMedGoogle Scholar
  • 87 Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. Mov Disord 1986; 1 (01) 45-49
    CrossrefPubMedGoogle Scholar
  • 88 Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995; 60 (01) 3-38
    CrossrefPubMedGoogle Scholar
  • 89 Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. Neurology 1993; 43 (3 Pt 1): 505-508
    CrossrefPubMedGoogle Scholar
  • 90 Arabia G, Grossardt BR, Colligan RC. , et al. Novelty seeking and introversion do not predict the long-term risk of Parkinson disease. Neurology 2010; 75 (04) 349-357
    CrossrefPubMedGoogle Scholar
  • 91 Bower JH, Grossardt BR, Maraganore DM. , et al. Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord 2010; 25 (13) 2105-2113
    CrossrefPubMedGoogle Scholar
  • 92 Tanner C, Albers K, Goldman S. , et al. Seborrheic dermatitis and risk of future Parkinson's disease (PD) (S42. 001). Neurology 2012; 78 (1, Suppl S42.001): 42
    CrossrefPubMedGoogle Scholar
  • 93 Gregory R, Miller S. Parkinson's disease and the skin. Pract Neurol 2015; 15 (04) 246-249
    CrossrefPubMedGoogle Scholar
  • 94 Huang P, Yang X-D, Chen S-D, Xiao Q. The association between Parkinson's disease and melanoma: a systematic review and meta-analysis. Transl Neurodegener 2015; 4 (01) 21
    CrossrefPubMedGoogle Scholar
  • 95 Bourghli A, Guérin P, Vital J-M. , et al. Posterior spinal fusion from T2 to the sacrum for the management of major deformities in patients with Parkinson disease: a retrospective review with analysis of complications. J Spinal Disord Tech 2012; 25 (03) E53-E60
    CrossrefPubMedGoogle Scholar
  • 96 Moon S-H, Lee H-M, Chun H-J. , et al. Surgical outcome of lumbar fusion surgery in patients with Parkinson disease. J Spinal Disord Tech 2012; 25 (07) 351-355
    CrossrefPubMedGoogle Scholar
  • 97 Sarkiss CA, Fogg GA, Skovrlj B, Cho SK, Caridi JM. To operate or not?: A literature review of surgical outcomes in 95 patients with Parkinson's disease undergoing spine surgery. Clin Neurol Neurosurg 2015; 134: 122-125
    CrossrefPubMedGoogle Scholar
  • 98 Friedman JH, Dighe G. Systematic review of caudal epidural injections in the management of chronic back pain. R I Med J (2013) 2013; 96 (01) 12-16
    PubMedGoogle Scholar